A new frontier is opening in the fight against cancer and other complex diseases, one that moves beyond the conventional strategy of simply destroying malignant cells and toward the more sophisticated approach of actively reprogramming them. In a significant leap forward for protein therapy, an
The persistent challenge of keeping participants engaged in clinical trials has long been treated as a problem that begins only after a patient has consented, but this narrow viewpoint overlooks the vast majority of individuals who disengage before ever setting foot in a clinic. For years, the
A groundbreaking collaboration is set to address a critical paradox in modern medicine, where potentially life-saving therapies for ultra-rare diseases are abandoned not for lack of scientific merit, but due to insufficient commercial appeal. The American Society of Gene & Cell Therapy (ASGCT) and
For the millions of people living with the relentless progression of Parkinson's disease, the daily battle for motor control has long been fought with a limited and often burdensome arsenal of treatments. The landscape of this fight is on the cusp of a dramatic transformation, however, as two
A comprehensive and detailed analysis from a recent study is reshaping the landscape of precision oncology, revealing the significant potential of whole-genome sequencing (WGS) to revolutionize how patient responses to PARP inhibitor cancer treatments are predicted. The findings, published in the
With the recent regulatory approval of two distinct gene therapies for sickle cell disease, patients and clinicians now face a pivotal and complex question regarding which groundbreaking treatment offers the best long-term solution. A landmark preclinical study published in Blood Advances provides
